Kory James Wentworth Sells 8,637 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 8,637 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $19.98, for a total transaction of $172,567.26. Following the completion of the transaction, the chief financial officer now directly owns 73,849 shares of the company’s stock, valued at approximately $1,475,503.02. This represents a 10.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Kory James Wentworth also recently made the following trade(s):

• On Monday, September 9th, Kory James Wentworth sold 3,195 shares of Entrada Therapeutics stock. The stock was sold at an average price of $14.97, for a total transaction of $47,829.15.

Entrada Therapeutics Stock Down 4.6 %

NASDAQ:TRDA opened at $19.04 on Friday. The company has a fifty day moving average of $16.62 and a 200 day moving average of $15.85. Entrada Therapeutics, Inc. has a 52 week low of $10.75 and a 52 week high of $20.49. The firm has a market capitalization of $712.48 million, a P/E ratio of 11.97 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The company had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million. As a group, analysts anticipate that Entrada Therapeutics, Inc. will post 1.07 EPS for the current year.

Analyst Ratings Changes

TRDA has been the subject of a number of research reports. HC Wainwright boosted their price target on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Oppenheimer upped their price objective on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th.

Institutional Investors Weigh In On Entrada Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TRDA. US Bancorp DE purchased a new stake in shares of Entrada Therapeutics in the 3rd quarter worth about $42,000. Acadian Asset Management LLC purchased a new stake in Entrada Therapeutics in the first quarter worth about $79,000. SG Americas Securities LLC bought a new stake in Entrada Therapeutics during the 3rd quarter valued at approximately $156,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Entrada Therapeutics by 427.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 14,763 shares of the company’s stock worth $209,000 after acquiring an additional 11,965 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Entrada Therapeutics by 34.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,156 shares of the company’s stock worth $226,000 after acquiring an additional 3,644 shares during the period. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.